| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69702 | (Rac)-IBT6A hydrochloride ((Rac)-ibrutinib) | 1807619-60-8 | (Rac)-IBT6A HCl is the racemate of IBT6A HCl. |
|
V3392 | (±)-Zanubrutinib | 1633350-06-7 | Zanubrutinib is a racemic mixture of Zanubrutinib (formerly known as BGB-3111) which is a novel, highly selective, second generation BTK inhibitor, currently under clinical investigation in hematological cancers. |
|
V69689 | BCPyr | 2669844-82-8 | BCPyr is a new candidate BTK degrader (DC50 = 800 nM). |
|
V3184 | BMS-935177 | 1231889-53-4 | BMS-935177 is a potent, selective, reversible, and 2nd generation inhibitor of Bruton’s Tyrosine Kinase (BTK) with an IC50 of 3 nM. |
|
V4066 | BMS-986142 | 1643368-58-4 | BMS-986142, a carbazole and tetrahydrocarbazole based compound, is a novel, potent and highly selective reversible Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 0.5 nM. |
|
V3807 | BMS-986195 | 1912445-55-6 | Branebrutinib (formerly BMS-986195) is a highly selective and rapidly acting covalent/irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK) with IC50 of<1 nM and robust efficacy at low doses in preclinical models of RA (Rheumatoid Arthritis) and Lupus Nephritishighly. |
|
V4782 | BMX-IN-1 | 1431525-23-3 | BMX-IN-1 is a novel, potent, selective and covalent / irreversible BMX (bone marrow tyrosine kinase on chromosome X) inhibitor with the potential for treating prostate cancer. |
|
V85502 | BTK-IN-30 | 2662512-15-2 | |
|
V85253 | BTK-IN-32 | 1015441-29-8 | |
|
V85343 | BTK-IN-33 | 2765854-31-5 | |
|
v2306 | BTK inhibitor 17 | 1858206-76-4 | BTK inhibitor 17 is a potent, orally bioactive, irreversible BTK inhibitor (antagonist) with IC50 of 2.1 nM. |
|
V69661 | Elsubrutinib (ABBV-105) | 1643570-24-4 | Elsubrutinib (ABBV-105) is an orally bioactive, specific and irreversible inhibitor of Bruton's tyrosine kinase (BTK). |
|
V69664 | Ibrutinib deacryloylpiperidine (IBT4A) | 330786-24-8 | Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. |
|
V4776 | QL47 | 1469988-75-7 | QL-47 (also known as QL-XII-47) is a novel, potent, selective and irreversible BTK kinase inhibitor with IC50 of 7 nM. |
|
V3391 | (R)-Zanubrutinib | 1691249-44-1 | R)-Zanubrutinib is the R-enantiomer of Zanubrutinib (formerly known as BGB-3111) which is a novel, highly selective, second generation BTK inhibitor, currently under clinical investigation in hematological cancers. |
|
V38770 | Orelabrutinib | 1655504-04-3 | Orelabrutinib (ICP-022;ICP022;ICP 022) is an oral bioavailable, new generation and irreversible/covalent Brutons tyrosine kinase (BTK) inhibitor with the potential to be used for the treatment of cancer such asB-cell lymphomas and autoimmune indications. |
|
V4678 | Tirabrutinib (ONO-4059) | 1351636-18-4 | Tirabrutinib (formerly ONO-4059; GS4059; ONO-WG-307; Steboronine) is a novel, potent, highly selective, covalent/irreversible and orally bioavailable BTK (Bruton agammaglobulinemia tyrosine kinase) inhibitor with anticancer activity. |
|
V3979 | ZANUBRUTINIB | 1691249-45-2 | Zanubrutinib (formerly known as BGB-3111), an S-enantiomer, is a novel, highly selective, second generation BTK inhibitor, currently under clinical investigation in hematological cancers. |
|
V2980 | Acalabrutinib (ACP-196) | 1420477-60-6 | Acalabrutinib (formerly known as ACP196; ACP-196; trade name:Calquence)is a selective second-generation Brutons tyrosine kinase (BTK) inhibitor with anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
